These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21489883)

  • 1. Outer-membrane-vesicle vaccines: old but not forgotten.
    Stephens DS
    Lancet Infect Dis; 2011 Jun; 11(6):421-2. PubMed ID: 21489883
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.
    Taha MK; Zarantonelli ML; Alonso JM; Naess LM; Holst J; Feiring B; Rosenqvist E
    Vaccine; 2007 Mar; 25(14):2537-8. PubMed ID: 16460845
    [No Abstract]   [Full Text] [Related]  

  • 3. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak.
    Caron F; du Châtelet IP; Leroy JP; Ruckly C; Blanchard M; Bohic N; Massy N; Morer I; Floret D; Delbos V; Hong E; Révillion M; Berthelot G; Lemée L; Deghmane AE; Bénichou J; Lévy-Bruhl D; Taha MK
    Lancet Infect Dis; 2011 Jun; 11(6):455-63. PubMed ID: 21489881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
    Sanders H; Feavers IM
    Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Meningococcal serogroup B vaccines].
    Dommergues MA
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S65-9. PubMed ID: 22883369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
    Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
    Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.
    Holst J; Feiring B; Naess LM; Norheim G; Kristiansen P; Høiby EA; Bryn K; Oster P; Costantino P; Taha MK; Alonso JM; Caugant DA; Wedege E; Aaberge IS; Rappuoli R; Rosenqvist E
    Vaccine; 2005 Mar; 23(17-18):2202-5. PubMed ID: 15755595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.
    Bai X; Borrow R
    Expert Rev Vaccines; 2010 Oct; 9(10):1203-17. PubMed ID: 20923270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines for prevention of group B meningococcal disease: Not your father's vaccines.
    Harrison LH
    Vaccine; 2015 Nov; 33 Suppl 4():D32-8. PubMed ID: 26116255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.
    Wedege E; Bolstad K; Aase A; Herstad TK; McCallum L; Rosenqvist E; Oster P; Martin D
    Clin Vaccine Immunol; 2007 Jul; 14(7):830-8. PubMed ID: 17494638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicted vs observed effectiveness of outer membrane vesicle (OMV) vaccines against meningococcal serogroup B disease: Systematic review.
    Harder T; Koch J; Wichmann O; Hellenbrand W
    J Infect; 2017 Aug; 75(2):81-94. PubMed ID: 28487177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.
    Findlow J; Taylor S; Aase A; Horton R; Heyderman R; Southern J; Andrews N; Barchha R; Harrison E; Lowe A; Boxer E; Heaton C; Balmer P; Kaczmarski E; Oster P; Gorringe A; Borrow R; Miller E
    Infect Immun; 2006 Aug; 74(8):4557-65. PubMed ID: 16861642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.
    Villena R; Safadi MAP; Valenzuela MT; Torres JP; Finn A; O'Ryan M
    Hum Vaccin Immunother; 2018 May; 14(5):1042-1057. PubMed ID: 29667483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines.
    Oviedo-Orta E; Ahmed S; Rappuoli R; Black S
    Vaccine; 2015 Jul; 33(31):3628-35. PubMed ID: 26093201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of MenB vaccines: prerequisites for clinical development.
    Sanders H; Kaaijk P; van den Dobbelsteen GP
    Expert Rev Vaccines; 2013 Jan; 12(1):31-42. PubMed ID: 23256737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B.
    Pillai S; Howell A; Alexander K; Bentley BE; Jiang HQ; Ambrose K; Zhu D; Zlotnick G
    Vaccine; 2005 Mar; 23(17-18):2206-9. PubMed ID: 15755596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two meningococcal B vaccines receive FDA 'breakthrough therapy' designation.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(6):1428-9. PubMed ID: 25396230
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.